Back

Taking injectable PrEP to scale: Optimising the value of lenacapavir for South Africa's HIV response

2025-12-15 health economics Title + abstract only
View on medRxiv
Show abstract

BackgroundSouth Africa accounts for 20% of the global HIV infections and has one of the highest HIV incidence rates in the world. Six-monthly injectable lenacapavir (LEN) for HIV pre-exposure prophylaxis (PrEP) has superior efficacy to oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), and similar efficacy to 2-monthly injectable cabotegravir (CAB). With LENs recent regulatory approval and the newly negotiated generic price of $40 per person per year, South Africa faces critical impleme...

Predicted journal destinations